Prior Presentation The work presented in this article has been published previously in abstract form: Bkdal TA, Borregaard J, Donsmark M, Breitschaft A, Sndergaard FL
Excessive growth signals from elevated glucose, causing increasing amounts of insulin needed to metabolize that glucose, lead to the acceleration of disease states
The FDA label emphasizes that gastrointestinal adverse reactions can be severe enough to cause dehydration in some patients, underscoring the importance of patient education and proactive symptom management to optimize treatment persistence
Tirzepatide produces faster weight loss but requires ongoing administration to maintain results
For example, patients may not know the source, strength, sterility controls, or labeling quality of a product
Valenti L